调价首日反应：非激素儿童湿疹药泽立美全网卖断货

Core Insights - The innovative drug Zeli Mei (Benvimod Cream) has been strongly recommended by the American Academy of Dermatology (AAD) for the treatment of atopic dermatitis, marking a significant recognition for a Chinese-developed medication [1] - Following this endorsement, the price of Zeli Mei was reduced from 980 yuan to 360 yuan, a decrease of 63%, leading to a surge in demand and stock shortages across major e-commerce platforms [1][2] Company Actions - Shanghai Zedeman Pharmaceutical Technology Co., Ltd. announced the price adjustment as part of its efforts to enhance drug accessibility, achieved through optimized production processes and increased capacity [2] - The company has committed to ensuring supply and accelerating the integration of the drug into various health insurance systems [2] Market Response - The market response to the price reduction has been overwhelmingly positive, with product inquiries increasing over 20 times on platforms like JD Health and Alibaba Health [1] - Experts highlight that the success of Zeli Mei reflects the organic combination of high quality and affordability in China's innovative drug sector, contributing positively to the health of the population [2]